-
EP2179744
European procedure
Extract from the Register of European Patents
EP About this file: EP2179744
| EP2179744 - Decreasing potential latrogenic risks associated with influenza vaccines [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 07.10.2011 Database last updated on 31.03.2026 | Most recent event Tooltip | 27.05.2022 | Lapse of the patent in a contracting state | published on 29.06.2022 [2022/26] | Applicant(s) | For all designated states Novartis Vaccines and Diagnostics GmbH Emil-von-Behring-Strasse 76 35041 Marburg / DE | [2010/17] | Inventor(s) | 01 /
Gregersen, Jens Peter Emil-von-Behring-Strasse 76 35041 Marburg / DE | [2010/17] | Representative(s) | Marshall, Cameron John, et al Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | [N/P] |
| Former [2010/17] | Marshall, Cameron John, et al Carpmaels & Ransford 43-45 Bloomsbury Square London WC1A 2RA / GB | Application number, filing date | 09075377.3 | 09.09.2005 | [2010/17] | Priority number, date | EP20040255471 | 09.09.2004 Original published format: EP 04255471 | [2010/17] | Previously filed application, date | WO2005IB03266 | 09.09.2005 | [2010/17] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP2179744 | Date: | 28.04.2010 | Language: | EN | [2010/17] | Type: | B1 Patent specification | No.: | EP2179744 | Date: | 01.12.2010 | Language: | EN | [2010/48] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 23.03.2010 | Classification | IPC: | A61K39/145, C12Q1/70 | [2010/17] | CPC: |
A61K39/145 (EP,US);
C12N7/00 (US);
A61K39/12 (EP,US);
A61P31/12 (EP);
A61P31/16 (EP);
A61P37/04 (EP);
C12Q1/70 (US);
C12Q1/701 (US);
G01N33/56983 (US);
C12N2760/16034 (US);
C12N2760/16051 (EP,US);
C12N2760/16134 (EP,US);
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2010/17] | Extension states | AL | 29.04.2010 | BA | 29.04.2010 | HR | 29.04.2010 | MK | 29.04.2010 | YU | 29.04.2010 | Title | German: | Verminderung von potentiellen iatrogenen Risiken in Verbindung mit Influenza Impfstoffen | [2010/17] | English: | Decreasing potential latrogenic risks associated with influenza vaccines | [2010/17] | French: | Diminution des risques iatrogènes potentiels associés aux vaccins contre la grippe | [2010/17] | Examination procedure | 21.08.2009 | Examination requested [2010/17] | 04.05.2010 | Amendment by applicant (claims and/or description) | 22.09.2010 | Communication of intention to grant the patent | 12.10.2010 | Fee for grant paid | 12.10.2010 | Fee for publishing/printing paid | Parent application(s) Tooltip | EP05795012.3 / EP1789084 | Opposition(s) | 02.09.2011 | No opposition filed within time limit [2011/45] | Fees paid | Renewal fee | 21.08.2009 | Renewal fee patent year 03 | 21.08.2009 | Renewal fee patent year 04 | 21.08.2009 | Renewal fee patent year 05 | 14.09.2010 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | TR | 01.12.2010 | [2022/26] | Documents cited: | Search | [X] US6344354 (WEBSTER ROBERT G et al.) | [A] EP1108787 (CRUCELL HOLLAND BV et al.) | [X] LEVANDOWSKI R A: "Regulatory perspective in the United States on cell cultures for production of inactivated influenza virus vaccines.", DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION. 1999, vol. 98, 1999, pages 171 - 175 ; dis, XP009060109, ISSN: 0301-5149 | [X] BRANDS R ET AL: "InfluvacTC: A safe Madin Darby Canine Kidney (MDCK) cell culture-based influenza vaccine", DEVELOPMENTS IN BIOLOGICAL STANDARDIZATION; INACTIVATED INFLUENZA VACCINES PREPARED IN CELL CULTURE S. KARGER AG, P.O. BOX, ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND; S. KARGER AG, NEW YORK, NEW YORK, USA SERIES : DEVELOPMENTS IN BIOLOGICAL S, 1999, & MEETING OF THE NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL; HERTS, ENGLAND, UK; SEPTEMBER 26-27, 1997, pages 93 - 100, XP009060107, ISSN: 3-8055-6896-7 | by applicant | US5948410 | WO9737000 | WO03076601 | WO2005042728 | WO9615231 | US6372223 | BRANDS ET AL., DEV BIOL STAND, vol. 98, 1999, pages 93 - 100 | HALPERIN ET AL., VACCINE, vol. 20, 2002, pages 1240 - 7 | TREE ET AL., VACCINE, vol. 19, 2001, pages 3444 - 50 | KISTNER ET AL., VACCINE, vol. 16, 1998, pages 960 - 8 | KISTNER ET AL., DEV BIOL STAND, vol. 98, 1999, pages 101 - 110 | BRUHL ET AL., VACCINE, vol. 19, 2000, pages 1149 - 58 | PAU ET AL., VACCINE, vol. 19, 2001, pages 2716 - 21 | PUPPE ET AL., J CLIN VIROL, vol. 30, 2004, pages 165 - 74 | LEARY ET AL., J CLIN MICROBIOL, vol. 40, 2002, pages 1368 - 75 | MAERTZDORF ET AL., J CLIN MICROBIOL, vol. 42, 2004, pages 981 - 6 | ERDMAN ET AL., J CLIN MICROBIOL, vol. 41, 2003, pages 4298 - 303 | MOSQUERA MDEL ET AL., J CLIN MICROBIOL, vol. 40, 2002, pages 111 - 6 | DEFFERNEZ ET AL., J CLIN MICROBIOL, vol. 42, 2004, pages 3212 - 3218 | COIRAS ET AL., J MED VIROL, vol. 72, 2004, pages 484 - 95 | REID ET AL., J VIROL METHODS, vol. 116, 2004, pages 169 - 76 | POON ET AL., J CLIN VIROL, vol. 30, 2004, pages 214 - 7 | CAMPSALL ET AL., J CLIN MICROBIOL, vol. 42, 2004, pages 1409 - 13 | HUANG ET AL., VET MICROBIOL, vol. 101, 2004, pages 209 - 14 | MAYALL ET AL., J CLIN PATHOL, vol. 56, 2003, pages 728 - 30 | WHILEY ET AL., JMED VIROL, vol. 72, 2004, pages 467 - 72 | HATTERMANN ET AL., XENOTRANSPLANTATION, vol. 11, 2004, pages 284 - 94 | NOVOA ET AL., VET RES, vol. 26, 1995, pages 493 - 8 | BLAKE ET AL., J CLIN MICROBIOL, vol. 33, 1995, pages 835 - 9 | HUCKRIEDE ET AL., METHODS ENZYMOL, vol. 373, 2003, pages 74 - 91 | GREENBAUM ET AL., VACCINE, vol. 22, 2004, pages 2566 - 77 | ZURBRIGGEN ET AL., EXPERT REV VACCINES, vol. 2, 2003, pages 295 - 304 | PIASCIK, JAM PHARM ASSOC (WASH DC)., vol. 43, 2003, pages 728 - 30 | MANN ET AL., VACCINE, vol. 22, 2004, pages 2425 - 9 | HALPERIN ET AL., AM J PUBLIC HEALTH, vol. 69, 1979, pages 1247 - 50 | HERBERT ET AL., J INFECT DIS, vol. 140, 1979, pages 234 - 8 | CHEN ET AL., VACCINE, vol. 21, 2003, pages 2830 - 6 | HEHME ET AL., VIRUS RES, vol. 103, 2004, pages 163 - 71 |